E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067584 |
E.1.2 | Term | Type 1 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Assessment of the linearity of the dose-response and dose-exposure relationship (based on AUCINS,0-10h, CMAX,INS, AUCGIR,0-10h, and GIRMAX ) of Dance 501 Human Insulin Inhalation Solution (INH) administered with the Dance 501 Inhaler |
|
E.2.2 | Secondary objectives of the trial |
• Assessment of the PK and PD responses at three doses of Dance 501 Human Insulin
Inhalation Solution administered with the Dance 501 Inhaler
• Assessment of the relative efficiency of Dance 501 Human Insulin Inhalation Solution
administered with the Dance 501 Inhaler compared to s.c. insulin lispro
• Safety and tolerability of Dance 501 Human Insulin Inhalation Solution administered with the Dance 501 Inhaler |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male and female subjects 18 to 55 years of age, inclusive
• Diagnosed with T1DM
• Body mass index (BMI) ≥ 18.5 and ≤ 30 kg/m2
• HbA1c ≤ 9.0 % inclusive
• Fasting C-peptide ≤ 0.30 nmol/L
• Treated with 2 or more daily injections of insulin or continuous s.c. insulin infusion for at least 6 months prior to screening
• Current total daily insulin treatment < 1.2 U/kg/day
• Non-smoker for ≥ 5 years prior to screening. Negative screening urine cotinine test
|
|
E.4 | Principal exclusion criteria |
• Any condition possibly affecting pulmonary drug absorption, in particular significant abnormalities in lung function testing, any active pulmonary disease, or treatment with bronchodilators
• Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer
• Any history or presence of clinically relevant comorbidity (with the exception of conditions associated with diabetes mellitus), or signs of acute illness, as judged by the Investigator
• Clinically significant abnormal values for hematology, biochemistry, coagulation, or urinalysis
• Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular autonomic neuropathy
• Recurrent severe hypoglycemia
• Current treatment with drugs which may interfere with glucose metabolism |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Pharmacokinetic Endpoints:
• AUCINS,0-10h, area under the human insulin and insulin lispro concentration-time curves from 0 to 10 hours (if AUCINS,0-10h cannot be reached, pre-defined restrictions will be followed (see section 13)
• CMAX,INS, maximum observed concentration of human insulin and of insulin lispro
Primary Pharmacodynamic Endpoints:
1. AUCGIR,0-10h, area under GIR-time curve from t=0 to 10 hours
2. GIRMAX, maximum observed GIR
Safety endpoints:
• Adverse events (including adverse device effects and hypoglycemic episodes)
• Clinical laboratory measures
• Physical examinations
• Vital signs
• Spirometry
• Electrocardiogram (ECG)
• Insulin antibodies |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary Pharmacokinetic Endpoints:
1. from t=0 to 10 hours
2. maximum observed concentration
Primary Pharmacodynamic Endpoints:
1. from t=0 to 10 hours
2. maximum observed GIR
Safety endpoints:
ongoing |
|
E.5.2 | Secondary end point(s) |
Secondary Pharmacokinetic Endpoints:
• Area under the insulin (INS) curves (AUCINS) for different time-intervals: AUCINS,0-1h, AUCINS,0-2h, AUCINS,0-8h
• Time to maximum insulin concentrations (tMAX,INS)
• Relative efficiency (FREL, dose corrected ratio of AUCINS,ALL for INH and s.c. insulin)
• Onset of appearance (time from trial product administration until the first time serum insulin concentration > LLOQ) (in case of different LLOQ values pre-defined restrictions will be followed (see section 13)
• Mean residence time of insulin (MRTINS)
Secondary Pharmacodynamic Endpoints:
• Area under the glucose infusion rate (GIR) curves (AUCGIR) for different time-intervals: AUCGIR,0-1h, AUCGIR,0-2h, AUCGIR,0-8h
• Time to maximum glucose infusion rate (tGIR,MAX)
• Relative biopotency (GREL, dose corrected ratio of AUCGIR 0-10h for INH and s.c. Insulin)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
as given in section E.5.2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |